Details for Patent: 9,241,915

Which drugs does patent 9,241,915 protect, and when does it expire?

Patent 9,241,915 protects OSPHENA and is included in one NDA.

This patent has twenty-nine patent family members in twenty-one countries.

Summary for Patent: 9,241,915

Title:	Method for enhancing the bioavailability of ospemifene
Abstract:	This invention relates to a method for enhancing the bioavailability of a therapeutically active compound of the formula (I) ##STR00001## or a geometric isomer, a stereoisomer, a pharmaceutically acceptable salt, an ester thereof or a metabolite thereof, wherein said compound is administered orally to the individual in connection with the intake of food.
Inventor(s):	Anttila; Markku (Turku, FI)
Assignee:	QuatRx Pharmaceuticals (Ann Arbor, MI)
Application Number:	14/310,822
Patent Claim Types: see list of patent claims	Use; Delivery;

Drugs Protected by US Patent 9,241,915

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	AB	RX	Yes	Yes						TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	AB	RX	Yes	Yes						TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
Duchesnay	OSPHENA	ospemifene	TABLET;ORAL	203505-001	Feb 26, 2013	AB	RX	Yes	Yes						TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE

International Family Members for US Patent 9,241,915

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1713458		CA 2015 00031	Denmark
European Patent Office	1713458		C300742	Netherlands
European Patent Office	1713458		92736	Luxembourg